ПЕДІАТРИЧНИЙ LONG COVID: СУЧАСНІ АСПЕКТИ, ПАТОГЕНЕЗ, КЛІНІКА, ДІАГНОСТИКА, ЛІКУВАННЯ (ОГЛЯД ЛІТЕРАТУРИ ТА ВЛАСНЕ СПОСТЕРЕЖЕННЯ)

  2. 2025
  3. ПЕДІАТРИЧНИЙ LONG COVID: СУЧАСНІ АСПЕКТИ, ПАТОГЕНЕЗ, КЛІНІКА, ДІАГНОСТИКА, ЛІКУВАННЯ (ОГЛЯД ЛІТЕРАТУРИ ТА ВЛАСНЕ СПОСТЕРЕЖЕННЯ)

Конюшевська А. А., Герасименко В. В., Кузеванова М. В., Сторожчук Ю. О.

ПЕДІАТРИЧНИЙ LONG COVID: СУЧАСНІ АСПЕКТИ, ПАТОГЕНЕЗ, КЛІНІКА, ДІАГНОСТИКА, ЛІКУВАННЯ (ОГЛЯД ЛІТЕРАТУРИ ТА ВЛАСНЕ СПОСТЕРЕЖЕННЯ)

Показати/Завантажити PDF

Про автора:

Конюшевська А. А., Герасименко В. В., Кузеванова М. В., Сторожчук Ю. О.

Рубрика:

ОГЛЯДИ ЛІТЕРАТУРИ

Тип статті:

Наукова стаття

Анотація:

Постковідний синдром є актуальною проблемою сучасної педіатрії. Клінічні симптоми Long COVID у дітей гетерогенні, неспецифічні, можуть відрізнятися за частотою та вираженістю, залежати від віку дитини. Більшість симптомів зменшуються з часом, однак можуть зберігатися упродовж року й довше, що здатне суттєво погіршувати повсякденне функціонування та якість життя дитини. Найпоширенішими проявами Long COVID у дітей є неврологічні та психіатричні симптоми, кардіореспіраторні порушення та симптоми ураження шлунково-кишкового тракту. Проведено аналіз літературних даних, присвячених COVID-19 і Long COVID у дітей. В огляді розглянуто ймовірний патогенез Long COVID, клінічні прояви, особливості перебігу захворювання у дітей, його поширеність, фактори ризику розвитку тривалого COVID, вплив різних вірусних варіантів SARS-CoV-2 з різною вірулентністю внаслідок мутацій, питання діагностики та лікування, вплив вакцинації, а також рекомендації щодо ведення дітей із Long COVID. На сьогодні опубліковано поодинокі дані щодо клінічних наслідків COVID-19 у дітей, які перенесли безсимптомні або легкі форми інфекції, що підлягає подальшому вивченню. Нами наведено власне клінічне спостереження підлітка з Long COVID. Розширення знань про клініку, особливості перебігу COVID у дітей, фактори ризику розвитку тривалих персистуючих симптомів, сприяє покращенню діагностики захворювання та тактики ведення пацієнтів. Велике значення має пошук маркерів, які можуть прогнозувати розвиток синдрому, допомагати в діагностиці та оцінювати ефективність терапії.

Теги:

групи ризику, діагностика, діти, клініка, тривалий COVID-19

Список цитованої літератури:

  1. Esposito S, Principi N, Azzari C, Cardinale F, di Mauro G, Galli L, et al. Italian intersociety consensus on management of long covid in children. Ital. J. Pediatr. 2022;48:42. DOI: 10.1186/s13052-022-01233-6.
  2. Esposito S, Deolmi M, Ramundo G, Puntoni M, Caminiti C, Principi N. True prevalence of long COVID in children: a narrative review. Front. Microbiol. 2023;14:1225952. DOI: 10.3389/fmicb.2023.1225952.
  3. Fainardi V, Meoli A, Chiopris G, Motta M, Skenderaj K, Grandinetti R, et al. Long COVID in Children and Adolescents. Life (Basel). 2022;12(2):285. DOI: 10.3390/life12020285.
  4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133-146. DOI: 10.1038/s41579-022-00846-2.
  5. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clin- ical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. DOI: 10.1016/S1473-3099(21)00703-9.
  6. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110:914-921. DOI: 10.1111/apa.15673.
  7. Stephenson T, Shafran R, Ladhani SN. Long COVID (Post-COVID-19 Condition) in Children: A Modified Delphi Process. Arch. Dis. Child. 2022;107(7):674-680. DOI: 10.1136/archdischild-2021-323624.
  8. World Health Organization. A Clinical Case Definition for Post COVID-19 Condition in Children and Adolescents by Expert Consensus. 2023. Geneva: WHO; 102 p. Available from: https://iris.who.int/server/api/core/bitstreams/ 269e1f3a-5fa9-475b-a22d-ac4df32d9628/con- tent.
  9. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. DOI:10.1136/ bmj.n1648.
  10. National Institute of Health. Long COVID Resources and Research about Long COVID. Bethesda: National Institute of Health; 2023. Available from: https://www.nhlbi.nih.gov/covid/long-covid.
  11. NICE. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19(NG188). London: National Institute for Health and Care Excellence (NICE); 2020. 50 p. Available from: http://www.nice.org.uk/ guidance/ng188/resources/covid19-rapid-guideline-managing-the- longterm-effects-of-covid19-pdf-66142028400325.
  12. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guide- line. The BMJ. 2021;372:n136. DOI: 10.1136/bmj.n136.
  13. Brackel CLH, Lap CR, Buddingh EP, Houten MA, van der Sande LJTM, Langereis EJ, et al. Pediatric long-COVID: An overlooked phenom- enon? Pediatr. Pulmonol. 2021;56(8):2495-2502. DOI: 10.1002/ppul.25521.
  14. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. JAMA. 2021;326(9):869-871. DOI: 10.1001/jama.2021.11880.
  15. Sterky E, Olsson-Аkefeldt S, Hertting O, Herlenius E, Alfven T, Rinder MR, et al. Persistent symptoms in Swedish children after hospital- isation due to COVID-19. Acta Paediatrica. 2021;110(9):2578-2580. DOI: 10.1111/apa. 15999.
  16. Sansone F, Pellegrino GM, Caronni A, Bonazza F, Vegni E, Lué A, et al. Long COVID in Children: A Multidisciplinary Review. Diagnostics (Basel). 2023;13(12):1990. DOI: 10.3390/diagnostics13121990.
  17. Huang Q, Wu X, Zheng X, Luo S, Xu S, Weng J. Targeting Inflammation and Cytokine Storm in COVID-19. Pharmacol. Res. 2020;159:105051. DOI: 10.1016/j.phrs.2020.105051.
  18. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The Trinity of COVID-19: Immunity, Inflammation and Intervention. Nat. Rev. Immunol. 2020;20(6):363374. DOI: 10.1038/s41577-020-0311-8.
  19. Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast Cell Activation Symptoms Are Prevalent in Long-COVID. Int. J. Infect. Dis. 2021;112:217226. DOI: 10.1016/j.ijid.2021.09.043.
  20. Biswas S, Thakur V, Kaur P, Khan A, Kulshrestha SKP. Blood Clots in COVID-19 Patients: Simplifying the Curious Mystery. Med. Hypotheses. 2021;146:110371. DOI: 10.1016/j.mehy.2020.110371.
  21. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TM- PRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052.
  22. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. DOI: 10.1038/s41591-021-01283-z.
  23. Yonts AB. Pediatric Long-COVID: A Review of the Definition, Epidemiology, Presentation, and Pathophysiology. Pediatr. Ann. 2022;51(11):e416-e420. DOI: 10.3928/19382359-20220913-06.
  24. Ha EK, Kim JH, Han MY. Long COVID in children and adolescents: prevalence, clinical manifestations, and management strategies. Clin Exp Pediatr. 2023;66(11):465-474. DOI: 10.3345/cep.2023.00472.
  25. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 Entry into Cells. Nat. Rev. Mol. Cell Biol. 2022;23(1):3-20. DOI:10.1038/s41580-021-00418-x.
  26. Lim S, Zhang M, Chang TL. ACE2-Independent Alternative Receptors for SARS-CoV-2. Viruses. 2022;14(11):2535. DOI: 10.3390/v14112535.
  27. Lee WS, Wheatley AK, Kent SJ, Dekosky B. Antibody-Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies. Nat. Microbiol. 2020;5:1185-1191. DOI: 10.1038/s41564-020-00789-5.
  28. Daher A, Balfanz P, Cornelissen C, Müller A, Bergs I, Marx N, et al. Follow up of Patients with Severe Coronavirus Disease 2019 (COVID-19): Pulmonary and Extrapulmonary Disease Sequelae. Respir. Med. 2020;174:106197. DOI: 10.1016/j.rmed.2020.106197.
  29. Sante GD, Buonsenso D, De Rose C, Valentini P, Ria F, Sanguinetti M, et al. Immune profile of children with post-acute sequelae of SARS- CoV-2 infection (Long COVID). MedRxiv. 2021. DOI: 10.1101/2021.05.07. 21256539.
  30. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208-2211. DOI: 10.1111/apa.15870.
  31. Buonsenso D, Pujol FE, Munblit D, Pata D, McFarland S, Simpson FK. Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: a survey of 510 children. Future Microbiol. 2022;17:577-588. DOI: 10.2217/fmb-2021-0285.
  32. Smane L, Stars I, Pucuka Z, Roge I, Pavare J. Persistent clinical features in paediatric patients after SARS-CoV-2 virological recovery: A retrospective population-based cohort study from a single centre in Latvia. BMJ Paediatr. Open. 2020;4(1):e000905. DOI: 10.1136/bmjpo-2020-000905.
  33. Fink TT, Marques HHS, Gualano B, Lindoso L, Bain V, Astley C, et al. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital. Clinics (Sao Paulo). 2021;76:e3511. DOI: 10.6061/clinics/ 2021/e3511.
  34. Erol N, Alpinar A, Erol C, Sari E, Alkan K. Intriguing new faces of Covid-19: Persisting clinical symptoms and cardiac effects in children. Cardiol. Young. 2022; 32(7):1085-1091. DOI: 10.1017/S1047951121003693.
  35. Esmaeilzadeh H, Sanaei Dashti A, Mortazavi N, Fatemian H, Vali M. Persistent Cough and Asthma-like Symptoms Post COVID-19 Hospitalization in Children. BMC Infect Dis. 2022;22(1):244. DOI: 10.1186/s12879-022-07252-2.
  36. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12:9950. DOI: 10.1038/s41598-022-13495-5.
  37. Zheng YB, Zeng N, Yuan K, Tian SS, Yang YB, Gao N, et al. Prevalence and risk factor for long COVID in children and adolescents: a meta-analysis and systematic review. J. Infect. Public Health. 2023;16:660-672. DOI: 10.1016/j.jiph.2023.03.005.
  38. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated Exhaustion Levels and Reduced Functional Diversity of T Cells in Peripheral Blood May Predict Severe Progression in COVID-19 Patients. Cell Mol. Immunol. 2020;17:541-543. DOI: 10.1038/s41423-020-0401-3.
  39. Roge I, Smane L, Kivite-Urtane A, Pucuka Z, Racko I, Klavina L, et al. Comparison of persistent symptoms after COVID-19 and other non- SARS-CoV-2 infections in children. Front. Pediatr. 2021;9:752385. DOI: 10.3389/fped.2021.752385.
  40. Kikkenborg Berg S, Palm P, Nygaard U, Bundgaard H, Petersen MNS, Rosenkilde S, et al. Long COVID symptoms in SARS-CoV-2- positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health. 2022;6:614-623. DOI: 10.1016/S2352-4642(22)00154-7.
  41. Trapani G, Verlato G, Bertino E, Maiocco G, Vesentini R, Spadavecchia A, et al. Long COVID-19 in children: an Italian cohort study. Ital J Pediatr. 2022;48:83. DOI: 10.1186/s13052-022-01282-x.
  42. Camporesi A, Morello R, La Rocca A, Zampino G, Vezzulli F, Munblit D, et al. Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study. E Clinical Medicine. 2024;76:102815. DOI: 10.1016/j.eclinm.2024.102815.
  43. Conde M, Gastesi I, de Pablo L, Villanueva-Medina S, Aguilera-Alonso D, Esteban A, et al. Persistent Symptoms (Lasting Longer than 1 Year) in Children Hospitalized with Acute COVID-19 Versus Other Conditions. Children (Basel). 2024;11(12):1444. DOI: 10.3390/children11121444.
  44. Ehm F, Tesch F, Menzer S, Loser F, Bechmann L, Vivirito A, et al. Long/post-COVID in children and adolescents: symptom onset and recovery after one year based on healthcare records in Germany. Infection. 2024;53(1):415-426. DOI: 10.1007/s15010-024-02394-8.
  45. Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, Ziv A, Bar-On O, Birk E, et al. Long COVID in children: observations from a designated pediatric clinic. Pediatr. Infect. Dis. J. 2021;40:e509-e511. DOI: 10.1097/INF.0000000000 003285.
  46. Leftin Dobkin SC, Collaco JM, McGrath-Morrow SA. Protracted Respiratory Findings in Children Post-SARS-CoV-2 Infection. Pediatr. Pulmonol. 2021;56(12):3682-3687. DOI: 10.1002/ppul.25671.
  47. Doležalová K, Tuková J, Pohunek P. The Respiratory Consequences of COVID-19 Lasted for a Median of 4 Months in a Cohort of Children Aged 2–18 Years of Age. Acta Paediatr. Int. J. Paediatr. 2022;111(6):1201-1206. DOI: 10.1111/apa.16297.
  48. Heiss R, Tan L, Schmidt S, Regensburger AP, Ewert F, Mammadova D, et al. Pulmonary Dysfunction after Pediatric COVID-19. Radiology. 2022;306(3):221250. DOI: 10.1148/radiol.221250.
  49. La Regina DP, Pepino D, Nenna R, Iovine E, Mancino E, Andreoli G, et al. Pediatric COVID-19 Follow-Up with Lung Ultrasound: A Prospective Cohort Study. Diagnostics (Basel). 2022;12(9):2202. DOI: 10.3390/diagnostics 12092202.
  50. Denina M, Pruccoli G, Scolfaro C, Mignone F, Zoppo M, Giraudo I, et al. Sequelae of COVID-19 in hospitalized children: A 4-months follow- up. Pediatr. Infect. Dis. J. 2020;39(12):e458-e459. DOI: 10.1097/INF.0000000 000002937.
  51. Denina M, Scolfaro C, Silvestro E, Pruccoli G, Mignone F, Zoppo M, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020;146(1):e20201157. DOI: 10.1542/peds.2020-1157.
  52. Musolino AM, Supino MC, Buonsenso D, Ferro V, Valentini P, Magistrelli A, et al. Lung Ultrasound in Children with COVID-19: Preliminary Findings. Ultrasound Med. Biol. 2020;46(8):2094-2098. DOI: 10.1016/j.ultrasmedbio. 2020.04.026.
  53. Caroselli C, Blaivas M, Falzetti S. Diagnostic Imaging in Newborns, Children and Adolescents Infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Is There a Realistic Alternative to Lung High-Resolution Computed Tomography (HRCT) and Chest X-Rays? A Systematic Review of the Literature. Ultrasound Med. Biol. 2021;47(11):3034-3040. DOI: 10.1016/j.ultrasmedbio.2021.07.015.
  54. Soldati G, Demi M. What Is COVID 19 Teaching Us about Pulmonary Ultrasound? Diagnostics (Basel). 2022;12(4):838. DOI: 10.3390/diagnostics 12040838.
  55. Buonsenso D, Di Giuda D, Sigfrid L, Pizzuto DA, Di Sante G, De Rose C, et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc Health. 2021;5(9):677-680. DOI: 10.1016/S2352-4642(21)00196-6.
  56. Miller F, Nguyen V, Navaratnam AM, Shrotri M, Kovar J, Hayward AC, et al. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. Pediatr. Infect. Dis. J. 2022;41:979-984. DOI:10.1097/INF.000000000000 3715.
  57. Rusetsky Y, Meytel I, Mokoyan Z, Fisenko A, Babayan A, Malyavina U. Smell Status in Children Infected with SARS-CoV-2.Laryngoscope. 2021;131(8):E2475-E2480. DOI: 10.1002/lary.29403.
  58. Meliante PG, Marcellino A, Altomari R, Testa A, Gallo A, Ralli M, et al. Smell and Taste in Children with COVID-19. Allergy Rhinol. 2022;13:21526575221144950. DOI: 10.1177/21526575221144950.
  59. Raad N, Ghorbani J, Mikaniki N, Haseli S, Karimi-Galougahi M. Otitis Media in Coronavirus Disease 2019: A Case Series. J. Laryngol. Otol. 2021;135(1):1-13. DOI: 10.1017/S0022215120002741.
  60. Meringer H, Mehandru S. Gastrointestinal Post-Acute COVID-19 Syndrome. Nat. Rev. Gastroenterol. Hepatol. 2022;19(6):345-346. DOI: 10.1038/s41575 -022-00611-z.
  61. Morello R, de Rose C, Cardinali S, Valentini P, Buonsenso D. Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review. Children (Basel). 2022;9(10):1446. DOI: 10.3390/children9101446.
  62. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur. J. Pediatr. 2022;181:1597-1607. DOI: 10.1007/s00431-021-04345-z.
  63. Mohamed DZ, Ghoneim ME-S, Abu-Risha SE-S, Abdelsalam RA, Farag MA Gastrointestinal and Hepatic Diseases during the COVID-19 Pandemic: Manifestations, Mechanism and Management. World J. Gastroenterol. 2021;27(28):4504-4535. DOI: 10.3748/wjg.v27.i28.4504.
  64. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal Symptoms and Fecal Shedding of SARS-CoV-2 RNA Suggest Prolonged Gastrointestinal Infection. Med. 2022;3(6):371-387.e9. DOI: 10.1016/j.medj.2022.04.001.
  65. Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rössler A, et al. Postacute COVID-19 Is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022;163(2):495-506.e8. DOI: 10.1053/j.gastro.2022.04.037.
  66. Yeoh YK, Zuo T, Lui GCY, Zhang F, Liu Q, Li AY, et al. Gut Microbiota Composition Reflects Disease Severity and Dysfunctional Immune Responses in Patients with COVID-19. Gut. 2021;70(4):698-706. DOI: 10.1136/gutjnl-2020-323020.
  67. De Almeida VM, Engel DF, Ricci MF, Cruz CS, Lopes IS, Alves DA, et al. Gut Microbiota from Patients with Mild COVID-19 Cause Alterations in Mice That Resemble Post-COVID Syndrome. Gut Microbes. 2023;15(2):2249146. DOI: 10.1080/19490976.2023.2249146.
  68. Cooper S, Tobar A, Konen O, Orenstein N, Kropach Gilad N, Landau YE, et al. Long COVID-19 Liver Manifestation in Children. J. Pediatr. Gastroenterol. Nutr. 2022;75(3):244-251. DOI: 10.1097/MPG.00000000 00003521.
  69. Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Clinical Characterization of Dysautonomia in Long COVID-19 Patients. Sci. Rep. 2021;11(1):14042. DOI: 10.1038/s41598-021-93546-5.
  70. Boris JR, Moak JP. Pediatric Postural Orthostatic Tachycardia Syndrome: Where We Stand. Pediatrics. 2022;150(1):e2021054945. DOI: 10.1542/peds. 2021-054945.
  71. Kokorelis C, Malone, L, Byrne K, Morrow A, Rowe PC. Onset of Postural Orthostatic Tachycardia Syndrome (POTS) Following COVID-19 Infection: A Pediatric Case Report. Clin. Pediatr. 2023;62(2):92-95. DOI: 10.1177/00099228221113609.
  72. Raj SR, Guzman JC, Harvey P, Richer L, Schondorf R, Seifer C, et al. Canadian Cardiovascular society position statement on postural orthostatic tachycardia syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Canadian Journal of Cardiology.2020;36(3):357-72. DOI: 10.1016/j.cjca.2019.12.024.
  73. Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting — Part 1. Auton Neurosci. 2021;235:102828. DOI: 10.1016/j. autneu.2021.102828.
  74. Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease. J Innov Card Rhythm Manag. 2020;11(11):4302-4304. DOI: 10.19102/icrm.2020.111102.
  75. Miglis MG, Prieto T, Shaik R, Muppidi S, Sinn DI, Jaradeh S. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30(5):449-451. DOI: 10.1007/s10286-020-00727-9.
  76. Petracek LS, Suskauer SJ, Vickers RF, Patel NR, Violand RL, Swope RL, et al. Adolescent and young adult ME/CFS after confirmed or probable COVID-19. Front Med (Lausanne). 2021;8:668944. DOI: 10.3389/fmed.2021.668944.
  77. Shechter A, Yelin D, Margalit I, Abitbol M, Morelli O, Hamdan A, et al. Assessment of Adult Patients with Long COVID Manifestations Suspected as Cardiovascular: A Single-Center Experience. J. Clin. Med. 2022;11(20):6123. DOI: 10.3390/jcm11206123.
  78. Sirico D, Di Chiara C, Costenaro P, Bonfante F, Cozzani S, Plebani M, et al. Left ventricular longitudinal strain alterationsin asymptomatic or mildly symptomatic paediatric patients with SARS-CoV-2 infection. Eur Heart J Cardiovasc Imaging. 2022;23(8):1083-1089. DOI: 10.1093/ ehjci/jeab127.
  79. Abdel-Moneim A, Hosni A. Insights into the possible impact of COVID-19 on the endocrine system. Arch. Physiol. Biochem. 2023;129(4):998- 1006. DOI: 10.1080/13813455.2021.1890131.
  80. Cherubini V, Gohil A, Addala A, Zanfardino A, Iafusco D, Hannon T. Unintended consequences of COVID-19: Remember general pediatrics. J. Pediatr. 2020;223(8):197-198. DOI: 10.1016/j.jpeds.2020.05.004.
  81. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020;36(7):e3319. DOI: 10.1002/dmrr.3319.
  82. Beshbishy AM, Oti VB, Hussein DE, Rehan IF, Adeyemi OS, Rivero-Perez N, et al. Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review. Front. Public Health. 2021;9:591982. DOI: 10.3389/fpubh.2021. 591982.
  83. Loh C, Weihe P, Kuplin N, Placzek K, Weihrauch-Blüher S. Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic. Metabolism. 2021;122:154842. DOI: 10.1016/j. metabol.2021.154842.
  84. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev. Endocr. Metab. Disord. 2020;22(4):803-815. DOI: 10.1007/s11154-020-09615-z.
  85. Caron P. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. Ann. Endocrinol. (Paris). 2020;81(5):507-510. DOI: 10.1016/j.ando.2020.09.0.
  86. Malik J, Malik A, Javaid M, Zahid T, Ishaq U, Shoaib M. Thyroid function analysis in COVID-19: A retrospective study from a single center. PLoS ONE. 2021;16(3):e0249421. DOI: 10.1371/journal.pone.0249421.
  87. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID19: the THYRCOV study. Eur. J. Endocrinol. 2020;183(4):381-387. DOI: 10.1530/EJE-20-0335.
  88. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute Thyroiditis After Sars-COV-2 Infection. J. Clin. Endocrinol. Metab. 2020;105(7):2367-2370. DOI: 10.1210/clinem/dgaa276.
  89. Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr. 2020;14(5):1429-1430. DOI: 10.1016/j.dsx.2020.07.044.
  90. Sparks MA, South AM, Badley AD, Baker-Smith CM, Batlle D, Bozkurt B, et al. Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensi System. Pressing Needs and Best Research Practices. Hypertension. 2020;76(5):1350-1367. DOI:10.1161/HYPERTENSIONA HA.120.15948.
  91. Pourfridoni M, Abbasnia SM, Shafaei F, Razaviyan J, Heidari-Soureshjani R. Fluid and Electrolyte Disturbances in COVID-19 and Their Complications. Biomed Res Int. 2021;2021:6667047. DOI: 10.1155/2021/6667047.
  92. Silva ACS, Lanza K, Palmeira VA, Costa LB, Flynn JT. 2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirus. Pediatr Nephrol. 2021;36(6):1407-1426. DOI: 10.1007/s00467-020-04759-1.
  93. Basaalely A, Gurusinghe S, Schnaider J, Shah SS, Siegel LB, Pollack G, et al. Acute Kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19. Kidney Int. 2021;100(1):138-145. DOI:10.1016/j.kint.2021. 02.026.
  94. Kari JA, Shalaby MA, Albanna AS, Alahmadi TS, Alherbish TS, Alhasan KA. Acute kidney injury in children with COVID-19: a retrospective study. BMS Nephrol. 2021;22(1):202. DOI: 10.1186/s12882-021-02389-9.
  95. Wang X, Chen X, Tang F, Luo W, Fang J, Qi C, et al. Be aware of acute kidney injury in critically ill children with COVID-19. Pediatr Nephrol. 2020;36(1):163-169. DOI: 10.1007/s00467-020-04715-z.
  96. Stewart DJ, Hartley JC, Johnson M, Marks SD, Pré P, Stojanovic J. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health. 2020;4(8):e28-e29. DOI: 10.1016/S2352-4642(20)30178-4.
  97. Baradaran A, Malek A, Moazzen N, Shaye ZA. COVID-19 Associated Multisystem Inflammatory Syndrome: A Systematic Review and Metaanalysis. Iran J Allergy Asthma Immunol. 2020;19(6):570-588. DOI: 10.18502/ijaai.v19i6.4927.
  98. Enia T, Morimota Y, Oshima R, Myazaki K, Miyazawa T, Okada M, et al. Nephrotic syndrome relapse in a boy with COVID-19. CEN Case Rep. 2021;10(3):431-434. DOI: 10.1007/s13730-021-00587-w.
  99. Alvarado A, Franceschi G, Resplandor E, Sumba J, Orta N. COVID-19 associated with onset nephrotic Syndrome in a pediatric patient: considinse or related conditions? Pediatr Nephrol. 2021;36(1):205-207. DOI: 10.1007/ s00467-020-04724-y.
  100. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and Clinical Presentation of Long COVID in Children: A Systematic Review. Eur. J. Pediatr. 2022;181(12):3995-4009. DOI: 10.1007/s00431-022-04600-x.
  101. Ariza ME. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human Herpesviruses Are Back! Biomolecules. 2021;11(2):185. DOI: 10.3390/biom11020185.
  102. Araja D, Berkis U, Lunga A, Murovska, M. Shadow Burden of Undiagnosed Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) on Society: Retrospective and Prospective-In Light of COVID-19. J. Clin. Med. 2021;10(14):3017. DOI: 10.3390/jcm10143017.
  103. Komaroff AL, Lipkin WI. Insights from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome May Help Unravel the Pathogenesis of Postacute COVID-19 Syndrome. Trends Mol. Med. 2021;27(9):895-906. DOI: 10.1016/j.molmed.2021.06.002.
  104. Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M, et al. Post-Acute COVID-19 Syndrome. Eur. Respir. Rev. 2022;31(163):210185. DOI: 10.1183/16000617.0185-2021.
  105. Tarantino S, Graziano S, Carducci C, Giampaolo R, Grimaldi Capitello T. Cognitive Difficulties, Psychological Symptoms, and Long Lasting Somatic Complaints in Adolescents with Previous SARS-CoV-2 Infection: A Telehealth Cross-Sectional Pilot Study. Brain Sci. 2022;12(8):969. DOI: 10.3390/brainsci12080969.
  106. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. N. Engl. J. Med. 2020;383(4):347-358. DOI: 10.1056/NEJMoa2021756.
  107. Lin JE, Asfour A, Sewell TB, Hooe B, Pryce P, Earley C, et al. Neurological Issues in Children with COVID-19. Neurosci. Lett. 2021;743:135567. DOI: 10.1016/j.neulet.2020.135567.
  108. Abel D, Shen MY, Abid Z, Hennigan C, Boneparth A, Miller EH, et al. Encephalopathy and Bilateral Thalamic Lesions in a Child with MIS-C Associated with COVID-19. Neurology. 2020;95(16):745-748. DOI: 10.1212/WNL.0000000000010652.
  109. Abdel-Mannan O, Eyre M, Löbel U, Bamford A, Eltze C, Hameed B, et al. Neurologic and Radiographic Findings Associated with COVID-19 Infection in Children. JAMA Neurol. 2020;77(11):1440-1445. DOI: 10.1001/jamaneurol.2020.2687.
  110. Dugue R, Cay-Martínez KC, Thakur KT, Garcia JA, Chauhan LV, Williams SH, et al. Neurologic Manifestations in an Infant with COVID-19. Neurology. 2020;94(24):1100-1102. DOI: 10.1212/WNL.000000000000 9653.
  111. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N. Engl. J. Med. 2020;383(4):334-346. DOI: 10.1056/NEJMoa2021680.
  112. Di Filippo P, Attanasi M, Dodi G, Porreca A, Raso M, di Pillo S, et al. Evaluation of Sleep Quality and Anxiety in Italian Pediatric Healthcare Workers during the First Wave of COVID-19 Pandemic. BMC Res. Notes. 2021;14(1):219. DOI: 10.1186/s13104-021-05621-9.
  113. Arora T, Grey I, Östlundh L, Lam KBH, Omar OM, Arnone D. The Prevalence of Psychological Consequences of COVID-19: A Systematic Review and Meta-Analysis of Observational Studies. J. Health Psychol. 2022;27(4):805-824. DOI: 10.1177/1359105320966639.
  114. Solmi M, Estradé A, Thompson T, Agorastos A, Radua J, Cortese S, et al. Physical and mental health impact of COVID-19 on children, adolescents, and their families: the collaborative outcomes study on health and functioning during infection times – children and adolescents (COH-FIT-C&a). J. Affect. Disord. 2022;299:367-376. DOI: 10.1016/j.jad.2021.09.090.
  115. Duan L, Shao X, Wang Y, Huang Y, Miao J, Yang X, et al. An Investigation of Mental Health Status of Children and Adolescents in China during the Outbreak of COVID-19. J. Affect. Disord. 2020;275:112-118. DOI: 10.1016/j.jad.2020.06.029.
  116. Panda PK, Gupta J, Chowdhury SR, Kumar R, Meena AK, Madaan P, et al. Psychological and Behavioral Impact of Lockdown and Quarantine Measures for COVID-19 Pandemic on Children, Adolescents and Caregivers: A Systematic Review and Meta-Analysis. J. Trop. Pediatr. 2021;67:fmaa122. DOI: 10.1093/tropej/fmaa122.
  117. Laura V-S, Javier F, Miguel AV. Psychological Wellbeing of Vulnerable Children during the COVID-19 Pandemic. Psicothema. 2020;32(4):501-507. DOI: 10.7334/psicothema2020.218.
  118. Liu JJ, Bao Y, Huang X, Shi J, Lu L. Mental Health Considerations for Children Quarantined Because of COVID-19. Lancet Child. Adolesc. Health. 2020;4(5):347-349. DOI: 10.1016/S2352-4642(20)30096-1.
  119. Stephenson T, Shafran R, De Stavola B, Ladhani S. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). BMJ Open. 2021;11(8):e052838 DOI: 10.1136/bmjopen-2021-052838.
  120. Martelletti P, Bentivegna E, Spuntarelli V, Luciani M. Long-COVID headache. SN Compr Clin Med. 2021;3(8):1704-1706. DOI:10.1007/s42399-021-00964-7.
  121. Perestiuk V, Sverstyuk A, Kosovska T, Volianska L, Boyarchuk OA. Predictive Model for the Development of Long COVID in Children. Int. J. Environ. Res. Public Health. 2025;22:1693. DOI: 10.3390/ijerph22111693.
  122. Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatr Infect Dis J. 2021;40:e482-e487. DOI: 10.1097/INF.0000000000003328.
  123. Rao S, Lee GM, Razzaghi H, Lorman V, Mejias A, Pajor NM, et al. Clinical features and burden of Postacute sequelae of SARS- CoV-2 infection in children and adolescents. JAMA Pediatr. 2022;176:1000-1009. DOI: 10.1001/jamapediatrics.2022.2800.
  124. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021;5(10):708-718. DOI: 10.1016/S2352-4642(21)00198-X.
  125. Molteni E, Absoud M, Duncan EL. Assessing the impact of the pandemic in children and adolescents: SARS-CoV-2 infection and beyond. Lancet Child Adolesc Health. 2022;6:216-217. DOI: 10.1016/S2352-4642(22)00035-9.
  126. Asadi-Pooya AA, Nemati H, Shahisavandi M, Akbari A, Emami A, Lotfi M, et al. Long COVID in children and adolescents. World J. Pediatr. 2021;17(5):495-499. DOI: 10.1007/s12519-021-00457-6.
  127. Morello R, Mariani F, Mastrantoni L, de Rose C, Zampino G, Munblit D, et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. EClinicalMedicine. 2023;59:101961. DOI: 10.1016/j.eclinm.2023.101961.
  128. Messiah SE, Xie L, Mathew MS, Shaikh S, Veeraswamy A, Rabi A, et al. Comparison of Long-term complications of COVID-19 illness among a diverse sample of children by MIS-C status. Int. J. Environ. Res. Public Health. 2022;19:13382. DOI: 10.3390/ijerph192013382.
  129. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health. 2021;5(6):e22-e23. DOI: 10.1016/S2352-4642(21) 00124-3.
  130. Puntoni M, Esposito S, Patrizi L, Palo CM, Deolmi M, Autore G, et al. Impact of age and sex interaction on post-acute sequelae of COVID-19: an Italian cohort study on adults and children. J. Clin. Med. 2023;12(8):2924. DOI: 10.3390/jcm12082924.
  131. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, et al. Effective public health measures to mitigate the spread of COVID-19: a systematic review. BMC Public Health. 2021;21(1):1015. DOI: 10.1186/s12889-021-11111-1.
  132. Agorastos A, Chrousos GP. The neuroendocrinology of stress: the stress-related continuum of chronic disease development. Mol. Psychiatry. 2022;27(1):502-513. DOI: 10.1038/s41380-021-01224-9.
  133. Dhawan M, Sharma A, Priyanka, Thakur N, Rajkhowa TK, Choudhary OP. Delta variant (B.1.617.2) of SARS-CoV-2: mutations, impact, challenges and possible solutions. Hum. Vaccin. Immunother. 2022;18(5):2068883. DOI: 10.1080/21645515.2022.2068883.
  134. Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed. Pharm. 2022;154:113522. DOI: 10.1016/j.biopha.2022.113522.
  135. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect. Dis. 2022;22(1):35-42. DOI: 10.1016/S1473-3099(21)00475-8.
  136. Wongwathanavikrom NB, Tovichien P, Udomittipong K, Palamit A, Tiamduangtawan P, Mahoran K, et al. Incidence and risk factors for long COVID in children with COVID-19 pneumonia. Pediatr. Pulmonol. 2024;59(5):1330-1338. DOI: 10.1002/ppul.26910.
  137. Tang C, Wang S, Fan J. A follow-up study of post-COVID-19 syndrome in hospitalized children with Omicron variant infection in Wuhan. Front. Pediatr. 2024;12:1359057. DOI: 10.3389/fped.2024.1359057.
  138. Khandia R, Singhal S, Alqahtani T, Kamal MA, El-Shall NA, Nainu F, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res. 2022;209:112816. DOI: 10.1016/j.envres.2022. 112816.
  139.  Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet. 2022;399(10335):1618-1624. DOI: 10.1016/S0140-6736(22) 00327-0.
  140. Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat. Commun. 2022;13(1):6856. DOI: 10.1038/s41467-022-34244-2.
  141. Wrenn JO, Pakala SB, Vestal G, Shilts MH, Brown HM, Bowen SM, et al. COVID-19 severity from omicron and Delta SARS-CoV-2 variants. Influenza Other Respir. Viruses. 2022;16(5):832-836. DOI: 10.1111/irv.12982.
  142. Fernández-de-las-Peñas C, Notarte KI, Peligro PJ, Velasco JV, Ocampo MJ, Henry BM, et al. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature. Viruses. 2022;14(12):2629. DOI: 10.3390/v14122629.
  143. Sumner MW, Xie J, Zemek R, Winston K, Freire G, Burstein B, et al. Comparison of symptoms associated with SARS-CoV-2 variants among children in Canada. JAMA Netw. Open. 2023;6:e232328. DOI: 10.1001/ jamanetworkopen.2023.2328.
  144. Butt AA, Dargham SR, Loka S, Shaik RM, Chemaitelly H, Tang P, et al. Coronavirus disease 2019 disease severity in children infected with the omicron variant. Clin. Infect. Dis. 2022;75(1):e361-e367. DOI: 10.1093/cid/ ciac275.
  145. Jank M, Oechsle AL, Armann J, Behrends U, Berner R, Chao CM. Comparing SARS-CoV-2 variants among children and adolescents in Germany: relative risk of COVID-19-related hospitalization, ICU admission and mortality. Infection. 2023;51(5):1357-1367. DOI: 10.1007/s15010-023-01996-y.
  146. Bahl A, Mielke N, Johnson S, Desai A, Qu L. Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing alpha, Delta, and omicron variants. Lancet Reg Health Am. 2023;18:100405. DOI: 10.1016/j.lana.2022.100405.
  147. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 2022;22(9):1293-1302. DOI: 10.1016/S1473-3099(22)00320-6.
  148. Chen J, Wang R, Gilby NB, Wei G-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022;62(2):412-422. DOI: 10.1021/acs.jcim.1c01451.
  149. Keyel AC, Russell A, Plitnick J, Rowlands JV, Lamson DM, Rosenberg E, et al. SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA. Emerg Infect Dis. 2022;28(10):1990-1998. DOI: 10.3201/eid2810.221058.
  150. Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385. DOI: 10.1136/bmjmed-2022-000385.
  151. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ Med. 2023;2:e000229. DOI: 10.1136/bmjmed-2022-000229.
  152. Edwards F, Hamilton FW. Impact of COVID-19 vaccination on Long COVID. BMJ Med. 2023;2:e000470. DOI: 10.1136/bmjmed-2022-000470.
  153. Tsilingiris D, Vallianou NG, Karampela I, Christodoulatos GS, Papavasileiou G, Petropoulou D, et al. Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges. Int. J. Mol. Sci. 2023;24(13):10458. DOI: 10.3390/ijms241310458.
  154. Morello R, Martino L, Buonsenso D. Diagnosis and Management of Post-COVID (Long COVID) in Children: A Moving Target. Curr. Opin. Pediatr. 2023;35(2):184-192. DOI: 10.1097/MOP.0000000000001221.
  155. Seylanova N, Chernyavskaya A, Degtyareva N, Mursalova A, Ajam A, Xiao L, et al. Core outcome measurement set for research and clinical practice in post-COVID-19 condition (long COVID) in children and young people: an international Delphi consensus study “PC- COS Children”. Eur Respir J. 2024;63:2301761. DOI: 10.1183/13993003.01761-2023.

Публікація статті:

«Вісник проблем біології і медицини», 2025 Випуск 4, 179, 32-56 сторінки, код УДК 616.98:578.834]-053.2-092-06-07-085

DOI:

10.29254/2077-4214-2025-4-179-32-56

2025 Випуск 4, 179
групи ризику діагностика діти клініка тривалий COVID-19
28.12.2025
Чи була ця стаття корисною?
1
1

Залишити відповідь

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *


The reCAPTCHA verification period has expired. Please reload the page.